Designed with patients in mind

A pleasant taste for your patients1

BUNAVAIL was designed with a likable, mild citrus taste to make it easier for your patients to administer their medicine as directed.

91.3% of patients switched from Suboxone® tablets or films to BUNAVAIL reported the taste of BUNAVAIL as very pleasant, pleasant, or neutral*

Low incidence of constipation is meaningful for your patients2

Part of fighting opioid dependence is patients getting back to the feeling of normalcy they experienced before the onset of addiction. In a survey of 606 patients conducted by the National Alliance of Advocates for Buprenorphine Treatment (NAABT):

74% reported constipation as a side effect of treatment

18% reported constipation as their “greatest frustration” with buprenorphine treatment

Decrease in patient-reported constipation1

This bar graph illustrates that 68%* of patients taking BUNAVAIL reported a resolution of their constipation. The y-axis measures the percentage of patients in increments of 20 from 0% to 80%. The left bar shows that at the beginning of the study, 41% of patients on Suboxone reported constipation symptoms. The right bar shows that at Week 12, 13% of patients reported constipation symptoms while taking BUNAVAIL, a change of 68%.
68% decrease in constipation

Based on data from a self-administered symptom checklist for patients (n=186) after 12 weeks of treatment with BUNAVAIL, who had previously discontinued treatment with Suboxone tablets or films.

2.8% (7/249) of patients reported treatment-emergent constipation

Speak and swallow normally during administration3

  • Absorption of buprenorphine is not affected by speaking or swallowing during administration
  • Patients should avoid manipulating film with their tongue or finger(s) and avoid drinking or eating food until the film dissolves
  • BUNAVAIL buccal film should not be chewed or swallowed as this may result in lower peak concentrations and lower bioavailability

Study Design: A 12-week, open-label, multicenter study assessed the safety and tolerability of BUNAVAIL buccal film for the maintenance treatment of opioid dependence in 249 subjects stabilized on 8/2 mg/day to 32/8 mg/day Suboxone tablet or film for at least 30 days.


  1. Sullivan JG, Webster L. Novel buccal film formulation of buprenorphine-naloxone for the maintenance treatment of opioid dependence: a 12-week conversion study. J Clin Ther. 2015;37(5):1064-1075.
  2. Soper RG, Bailey GL, Lepak T, Miller MM, Ziebro M. A survey of opioid-dependent patients treated with buprenorphine—self-reported side effects. Poster presented at: 26th Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry; December 3-6, 2015; Huntington Beach, CA.
  3. Vasisht N, Stark J, Bai SA, Finn A. Buprenorphine/naloxone buccal film has a relative buprenorphine bioavailability approximately twice that of buprenorphine/naloxone sublingual tablet. Poster presented at: 45th Annual American Society of Addiction Medicine (ASAM); April 10-13, 2014; Orlando, FL.



BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) is a prescription medicine indicated for the maintenance treatment of opioid dependence. BUNAVAIL should be used as part of a complete treatment plan to include counseling and psychosocial support.

Prescription use of this product is limited under the Drug Addiction Treatment Act (DATA).


Keep BUNAVAIL (buprenorphine and naloxone) buccal film (CIII) out of the sight and reach of children. Ingestion of BUNAVAIL by a child may cause severe breathing problems and death. If a child takes BUNAVAIL, get emergency help right away.

Do not take BUNAVAIL if you are allergic to buprenorphine or naloxone, as serious negative effects including anaphylactic shock, have been reported.

Do not take BUNAVAIL before the effects of other opioids (e.g., heroin, methadone, oxycodone, morphine) have lessened as you may experience withdrawal symptoms.

Do not drive, operate heavy machinery, or perform any other dangerous activities until you know how BUNAVAIL affects you.

BUNAVAIL contains buprenorphine, an opioid that can cause physical dependence. Your doctor can tell you more about the difference between physical dependence and drug addiction. Do not stop taking BUNAVAIL without talking to your doctor. You could become sick with uncomfortable withdrawal symptoms because your body has become used to this medicine.

Do not switch from BUNAVAIL to other medicines that contain buprenorphine without talking with your doctor. The amount of buprenorphine in a dose of BUNAVAIL is not the same as the amount of buprenorphine in other medicines. Your doctor will prescribe a dose of BUNAVAIL that may be different than other buprenorphine-containing medicines you may have been taking.

BUNAVAIL can cause serious life-threatening breathing problems, overdose and death, particularly when taken by the intravenous (IV) route in combination with benzodiazepines, sedatives, tranquilizers or alcohol. You should not drink alcohol while taking BUNAVAIL, as this can lead to loss of consciousness or even death.

Like other opioids (e.g., heroin, methadone, oxycodone, morphine), BUNAVAIL may produce orthostatic hypotension ('dizzy spells') in ambulatory individuals.

Common side effects of BUNAVAIL include headache, drug withdrawal syndrome, lethargy (lack of energy), sweating, constipation, decrease in sleep (insomnia), fatigue and sleepiness.

Because BUNAVAIL contains naloxone, injecting BUNAVAIL may cause serious withdrawal symptoms such as pain, cramps, vomiting, diarrhea, anxiety, sleep problems, and cravings.

BUNAVAIL can be abused in a manner similar to other opioids, legal or illicit. Keep BUNAVAIL in a safe place. Do not give your BUNAVAIL to other people, it can cause them harm or even death. Selling or giving away this medicine is against the law.

BUNAVAIL is not recommended in patients with severe hepatic impairment. BUNAVAIL may be used with caution for maintenance treatment in patients with moderate hepatic impairment.

Before taking BUNAVAIL, tell your doctor if you are pregnant or plan to become pregnant. If you become pregnant while taking BUNAVAIL, tell your doctor immediately as there may be significant risks to you and your baby; your baby may have symptoms of withdrawal at birth.

Before taking BUNAVAIL, talk to your doctor if you are breast-feeding or plan to breast-feed your baby. BUNAVAIL can pass into your breast milk and may harm your baby. Monitor your baby for increased sleepiness and breathing problems. Your doctor should tell you about the best way to feed your baby if you are taking BUNAVAIL.

This is not a complete list of potential adverse events associated with BUNAVAIL buccal film. Please see full Prescribing Information for a complete list.

To report negative side effects associated with taking BUNAVAIL buccal film, please call 1-800-469-0261. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

For more information, please see full Prescribing Information and Medication Guide for BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII).



BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) is a prescription medicine indicated for the maintenance treatment of opioid dependence. BUNAVAIL should be used as part of a complete treatment plan to include counseling and psychosocial support.